- Home
- TOPS vs ANTX Comparison
TOPS vs ANTX Comparison
Compare TOPS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- ANTX
- Stock Information
- Founded
- TOPS 2000
- ANTX 2017
- Country
- TOPS Greece
- ANTX United States
- Employees
- TOPS N/A
- ANTX N/A
- Industry
- TOPS Marine Transportation
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- ANTX Health Care
- Exchange
- TOPS Nasdaq
- ANTX Nasdaq
- Market Cap
- TOPS 27.4M
- ANTX 33.2M
- IPO Year
- TOPS 2004
- ANTX 2022
- Fundamental
- Price
- TOPS $5.90
- ANTX $1.07
- Analyst Decision
- TOPS
- ANTX Buy
- Analyst Count
- TOPS 0
- ANTX 2
- Target Price
- TOPS N/A
- ANTX $2.00
- AVG Volume (30 Days)
- TOPS 110.7K
- ANTX 287.0K
- Earning Date
- TOPS 08-08-2025
- ANTX 08-12-2025
- Dividend Yield
- TOPS N/A
- ANTX N/A
- EPS Growth
- TOPS N/A
- ANTX N/A
- EPS
- TOPS 1.09
- ANTX N/A
- Revenue
- TOPS $86,127,000.00
- ANTX N/A
- Revenue This Year
- TOPS $9.90
- ANTX N/A
- Revenue Next Year
- TOPS N/A
- ANTX N/A
- P/E Ratio
- TOPS $5.42
- ANTX N/A
- Revenue Growth
- TOPS 3.83
- ANTX N/A
- 52 Week Low
- TOPS $5.00
- ANTX $0.87
- 52 Week High
- TOPS $11.47
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- TOPS 46.93
- ANTX 45.19
- Support Level
- TOPS $5.74
- ANTX $1.07
- Resistance Level
- TOPS $6.00
- ANTX $1.11
- Average True Range (ATR)
- TOPS 0.47
- ANTX 0.04
- MACD
- TOPS -0.04
- ANTX 0.00
- Stochastic Oscillator
- TOPS 37.71
- ANTX 15.04
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.